Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.
Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.